Phathom Pharmaceuticals (PHAT) Non-Current Assets (2019 - 2026)
Phathom Pharmaceuticals (PHAT) posted quarterly Non-Current Assets of $31.2 million for Q2 2026, down 0.59% year-over-year from $31.3 million in Q2 2025, and up 9.15% quarter-over-quarter from $28.5 million in Q1 2026.
Phathom Pharmaceuticals (PHAT) Non-Current Assets (2019 - 2026) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has reported Non-Current Assets for 8 consecutive years, with $31.2 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Non-Current Assets fell 0.59% year-over-year to $31.2 million; the TTM figure through Jun 2026 stood at $122.4 million (up 32.95% YoY), while the FY2025 annual figure was $30.2 million, up 65.95% from the prior year.
- Non-Current Assets grew to $31.2 million in Q2 2026 per PHAT's latest filing, from $28.5 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $32.5 million in Q3 2025 and bottomed at $3.3 million in Q1 2022.
- Historically, Non-Current Assets has averaged $16.6 million across 5 years, with a median of $15.4 million in 2024.
- Annual changes were most pronounced in 2022 — Non-Current Assets dropped 6.9% — and 2024, when it soared 288.41%.
- Phathom Pharmaceuticals' Non-Current Assets stood at $4.3 million in 2022, then soared by 281.81% to $16.4 million in 2023, then gained by 10.81% to $18.2 million in 2024, then jumped by 65.95% to $30.2 million in 2025, then advanced by 3.26% to $31.2 million in 2026.
- Business Quant data shows PHAT's Non-Current Assets at $31.2 million in Q2 2026, $28.5 million in Q1 2026, and $30.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Phathom Pharmaceuticals | 767.07 Mn | 581.73 Mn | 59.18 Mn | 31.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 31.16 Mn |
| Mar 31, 2026 | 28.55 Mn |
| Dec 31, 2025 | 30.18 Mn |
| Sep 30, 2025 | 32.51 Mn |
| Jun 30, 2025 | 31.35 Mn |
| Mar 31, 2025 | 29.31 Mn |
| Dec 31, 2024 | 18.18 Mn |
| Sep 30, 2024 | 13.22 Mn |
| Jun 30, 2024 | 14.59 Mn |
| Mar 31, 2024 | 16.19 Mn |
| Dec 31, 2023 | 16.41 Mn |
| Sep 30, 2023 | 10.27 Mn |
| Jun 30, 2023 | 7.32 Mn |
| Mar 31, 2023 | 4.17 Mn |
| Dec 31, 2022 | 4.30 Mn |
| Sep 30, 2022 | 4.12 Mn |
| Jun 30, 2022 | 4.25 Mn |
| Mar 31, 2022 | 3.31 Mn |
| Dec 31, 2021 | 2.91 Mn |
| Sep 30, 2021 | 3.06 Mn |